Formulation and Drug Delivery, Controlled Release

OptiGel DR softgel capsules are formed by the combination of pectin, a naturally derived polysaccharide, and gelatin, which eliminates the need for a separate capsule coating step.

This study suggests that using a simple centrifugal method can produce a natural polymer-blend molecule that can successfully be used as an oral delivery mechanism for poorly soluble drugs.

Controlled-release formulations offer numerous advantages for developers and patients, and this market is expected to continue to experience growth in the near future.

Research examined the effects of varying excipient and polymer weight in coatings designed to optimize the release of diclofenac sodium. The goal was to release it at night to improve the treatment of rheumatoid arthritis.

Lipid-based formulations provide a versatile solution to bioavailability issues, but a multi-disciplinary approach is needed to overcome limitations with poorly soluble compounds.

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of AstraZeneca’s Qtrilmet (metformin hydrochloride, saxagliptin, and dapagliflozin) modified-release tablets for treating type-2 diabetes.

A design strategy can ensure conflicting properties are managed appropriately for multi-API controlled-release formulations.

An agreement with Sanofi gives Catalent access to commercial spray drying facility in Haverhill, UK.

Modified-release oral dosage forms can offer benefits to both formulation scientists and patients.

Understanding the API, delivery mechanism, and excipient functionality is essential to solving drug solubility challenges.

The challenge of achieving sustained delivery of an active ingredient or nutrient can be achieved with extended-release formulations.

This article demonstrates how qualitative physical attributes testing can be used to characterize soft gel capsule rupture/disintegration during rectal administration.

Lipid-based formulations offer a means of addressing the physicochemical and biological challenges of poorly soluble APIs.

Pharmaceutical companies are developing new strategies to address the ever-increasing development costs for new drug therapies and maximize the value of their existing drug portfolio.

This article describes the approaches used during the development of a dexlansoprazole delayed-release orally disintegrating tablet (ODT) to evaluate tablet size and texture as they relate to disintegration rate and patient experience; in addition, the resistance to alcohol was also characterized.

With the right excipients, formulators can control when, where, and how an API is released.

New approaches enable more patient-centric drug design that offers improved outcomes.

Assessing potential formulation and manufacturing issues in early development phases can improve a drug’s chances for success.

Orbis Biosciences’ Optimµm Platform delivers microparticulate dosage forms with controlled-release and taste-masked properties in a single manufacturing step.

Modified-release lipid-based formulations in softgel capsules can address physiochemical and pharmacokinetic challenges posed by drug compounds.

Poly(lactide-glycolide) has been used for drug-delivery applications because of its beneficial physicochemical properties, long safety record, and reliable commercial supply.

The patent was filed for a chewing gum composition with controlled release of cannabinoids and opioid agonists, and antagonists for addiction or dependence treatment.

Process analytical technology, based on monitoring particle size distribution and tracking coating thickness measurements in real time, can be used to predict the dissolution of polymer-coated multiparticulates.

Emerging controlled-release technologies could lead to more effective therapies in the near future.

PolySciTech's new launch, SpinSwiper, has the potential to speed up microparticle production.

Industry experts share their perspectives on key advances in controlled-release drug delivery and future innovations in this arena.

Lifecycle management opportunities are impacting the development of controlled-release technologies for solid-dosage drugs.

Researchers at Massachusetts recently reported on the development of a drug-eluting contact lens designed to provide prolonged delivery of the glaucoma medication, latanoprost.

Formulation and process considerations for ethyl cellulose aqueous dispersion in sustained-release applications.